프로트롬빈 복합체 농축액(PCC) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Prothrombin Complex Concentrate Market size is expected to reach USD 7.07 Billion in 2034 from USD 3.05 Billion (2025) growing at a CAGR of 9.79% during 2026-2034.

The global prothrombin complex concentrate (PCC) market has been witnessing steady growth due to the rising prevalence of bleeding disorders and increasing use in emergency anticoagulation reversal. Hospitals and trauma centers are increasingly adopting PCC products because of their rapid action compared to traditional plasma therapies. The growing number of surgeries and trauma cases has further contributed to demand, especially in developed healthcare systems where advanced treatment options are readily available.

Key drivers include the increasing use of anticoagulant therapies, particularly for cardiovascular diseases, which creates a parallel demand for reversal agents like PCC. Additionally, advancements in plasma fractionation technologies and improved safety profiles have enhanced product adoption. Government support and favorable reimbursement policies in several regions are also encouraging wider use of these concentrates in clinical practice.

Looking ahead, the market is expected to expand with ongoing research into improved formulations and broader clinical applications. Emerging markets are likely to offer significant growth opportunities due to improving healthcare infrastructure. Furthermore, increasing awareness among healthcare professionals regarding rapid bleeding management is expected to boost demand, positioning PCC as a critical component in emergency medicine globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• 4-Factor PCC
• 3-Factor PCC

By Application

• Acquired Coagulation Factor Deficiency
• Congenital Coagulation Factor Deficiency
• Other Applications

By End Use

• Hospitals
• Ambulatory Surgical Centers
• Other End Users

COMPANIES PROFILED

• CSL, Baxter, Emergent BioSolutions, Grifols Biologicals, Intas Pharmaceuticals, Kedrion Biopharma, LFB Group, Octapharma, Pfizer, Prothya Biosolutions, Takeda Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. 4-Factor PCC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. 3-Factor PCC Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Acquired Coagulation Factor Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Congenital Coagulation Factor Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Application
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Application
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Application
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Application
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Application
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROTHROMBIN COMPLEX CONCENTRATE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 CSL
  • 9.2.2 Baxter
  • 9.2.3 Emergent BioSolutions
  • 9.2.4 Grifols Biologicals
  • 9.2.5 Intas Pharmaceuticals
  • 9.2.6 Kedrion Biopharma
  • 9.2.7 LFB Group
  • 9.2.8 Octapharma
  • 9.2.9 Pfizer
  • 9.2.10 Prothya Biosolutions
  • 9.2.11 Takeda Pharmaceuticals